To The Editor, I wish to congratulate Amelot for their article [1] in which they assessed the effect of primary tumor systemic chemotherapy treatment on brain metastases localization. A total of 413 patients who underwent treatment for brain metastasis were included. The identification of all previous anticancer drugs received by patients from primary tumor diagnosis to brain metastases diagnosis was collated. They identified that the only independent factors associated with short brain metastasis-free survival (bMFS) were lung primary tumor and mitotic spindle inhibitor (taxanes) chemotherapy. However, among primary tumors, only patients with non-small cell cancers and breast cancer patients received taxanes. Concentrating breast cancer patients only, breast cancer patients commonly receive adjuvant taxanes for higherrisk patients (lymph node-positive patients) except patients with HER-2-positive disease. In other words, if breast cancer patients received taxanes, it means those have worse prognosis and have more chance to develop brain metastasis. This issue should be revised in the current study as well.
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